Compare · BDX vs CODX
BDX vs CODX
Side-by-side comparison of Becton Dickinson and Company (BDX) and Co-Diagnostics Inc. (CODX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and CODX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 9698.0x CODX ($5.4M).
- Over the past year, BDX is up 1.4% and CODX is down 93.4% - BDX leads by 94.8 points.
- CODX has been more active in the news (12 items in the past 4 weeks vs 9 for BDX).
- BDX has more recent analyst coverage (25 ratings vs 3 for CODX).
- Company
- Becton Dickinson and Company
- Co-Diagnostics Inc.
- Price
- $191.68-1.09%
- $0.64-10.79%
- Market cap
- $52.78B
- $5.4M
- 1M return
- +5.72%
- -32.14%
- 1Y return
- +1.38%
- -93.43%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 9
- 12
- Recent ratings
- 25
- 3
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Co-Diagnostics Inc.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and liquid biopsy test for cancer screening. The company also provides tests that identify genetic traits in plant and animal genomes. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest CODX
- SEC Form 8-K filed by Co-Diagnostics Inc.
- Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
- Amendment: SEC Form 8-K/A filed by Co-Diagnostics Inc.
- SEC Form 8-K filed by Co-Diagnostics Inc.
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
- Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
- Co-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Co-Diagnostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week